Business & Finance
Premaitha signs USD1m collaboration agreement in Taiwan
4 October 2018 -

UK-based molecular diagnostics group Premaitha Health plc (AIM: NIPT) will deliver next-generation sequencing (NGS) testing in the field of oncology to a clinical research organisation in Taiwan under a new partnership agreement announced on Thursday.

In the first phase of the partnership, Premaitha's Yourgene Bioscience division will provide genetic testing services using NGS technology on patient samples gathered by the unnamed partner company for the purpose of research into early-stage cancer screening.

The initial phase is anticipated to generate approximately USD1m of revenues over the next 6-12 months, and further project phases are anticipated in the future.

"This collaboration helps provide greater revenue visibility as we look to execute on our strategy of becoming a truly global business," commented Premaitha CEO Lyn Rees. "I am delighted to partner with an organisation of this breadth and scale, and look forward to sharing future progress as we continue to extend our offering."